I have been banging on this share will pick up momentum after August and certainly I have been quiet doing that topping up...I have been in this one too long, almost know when the good time would come, don't forget once or twice a year only. For anyone who came on here saying that they wished they would sell at this or that price, so make sure to think about that if you manage to recoup your losses. The one main reason I am not making money in AIM because of the the greed otherwise I would be in decent position, 9 out of 10 shares I ever invested in at some point I was in paper profit but kept wanting multi-bags.
Forget about 101, it won't happen until some income coming in first, even they start talking about clinical trials for 101 today, it won't happen until at the earliest sometimes in 2018. We have 2 obvious evidence right in front of us so why need to raise false expectations. Even one success either 201 or 401 would leave most on here happy including B I guess. Whoever from B managed to get the deal with VAL should get decent pay raise and upgrade his position.
I think that 4 phase 2b trials are likely for 201 next year. Prostrate, Breast and Ovarian cancers and Endometriosis.
401 might well trigger an additional phase 2 trial for pancreatic cancer, but the reality is that there is quite a long list of Adenocarcinomas that can be targeted.
They will all need partners to come on-board, which makes this a very interesting time.
GeneICE 101 should also progress to trial next year. And that's very exciting as that's a genuine potential cancer cure, based on an immunotherapy type approach by helping the human immune system to kill cancer cells through natural apoptosis.
issued [today] for a circa 19.35% rise . . . wow, I'm amazed!
Now things may finally begin to get a little more interesting here if, we do indeed observe a steady and sustained sp rise over the course of the next few trading sessions. If so, then the question which will be answered is, whether the BOD, Nomad and Broker 'choose' to once again 'kill the sp rise in its tracks' and in so doing, confirm beyond any and all reasonable doubt and suspicion that they are indeed, as I have long suspected, complicit in the manipulation of this company's sp and in so being, are working in a diametrically opposed manner to the interests of their shareholders or, as should be the case, they permit 'The Market' (with all its imperfections), to determine and ascribe Valirx true and fair value via the company's re-rated sp/market cap. After all and lest we forget, we are at the very least, some 83.33% of the way through our 'pivotal' 201 clinical trial and whilst news-flow has been 'sporadic' at best we have, none-the-less, received the occasional and ongoing assurance from 'Morris' that "it's working" and where that not the case then the 'triumvirate' (i.e. BOD, Broker, Nomad) would, have been duty bound and legally obligated to inform us the shareholders, along with 'The Market' of such a material fact via an appropriately worded RNS with immediate effect.
Which of the above scenarios will 'play-out' I wonder? All will be revealed in the fullness of time!
Datafeed and UK data supplied by NBTrader and Digital Look.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.